Multiple Ascending Dose study for AZD 7268 in Japanese Healthy Male Volunteers - JMAD

Study identifier:D1151C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Single-Centre, Randomised, Double-Blind, Placebo-controlled, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7268 When Given in Multiple Ascending Oral Doses in Japanese Healthy Male Subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD7268, Placebo

Sex

Male

Actual Enrollment

Study type

Interventional

Age

20 Years - 45 Years

Date

Study Start Date: 01 Apr 2010

Primary Completion Date: 01 Jul 2010

Study Completion Date: 01 Jul 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Other

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Location

Research Site

KANAGAWA, SAGAMIHARA, Japan

Arms	Assigned Interventions
Experimental: AZD7268	Drug: AZD7268 Capsule, Oral, BID
Placebo Comparator: Placebo	Drug: Placebo Capsule, Oral, BID

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1739&filename=CSR-D1151C00004.pdf
Download
CSR-D1151C00004.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Tomoe Fujita

Kitasato University East Hospital, Kanagawa, Japan